We speculate that a pharmacological inhibitor or ADAR1 might be useful to abrogate this suppression that possibly reactivates the IFN response in tumor microenvironment, which may recover anti-tumor immune function in gastric cancer. The gene discussed is ADAR; the disease is gastric cancer.